Exploring the Bone Marrow Environment in Childhood Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the role of the bone marrow microenvironment in acute childhood leukemia, focusing on how it may contribute to treatment resistance. It aims to understand the interactions between leukemia cells and mesenchymal stromal cells (MSCs), particularly regarding energy metabolism. By analyzing biological samples from children diagnosed with acute lymphoblastic or myeloblastic leukemia, as well as control patients undergoing orthopedic surgery, the study seeks to uncover mechanisms that could lead to improved treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* for patients with AL:

  1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
  2. Not having received prior hematological treatment
  3. Aged 1 to 15 years old
  4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
  5. Affiliated patient or beneficiary of a social security scheme.
* Control group patients:

  1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
  2. Aged between 1 and 15 years old.
  3. Having no pathology of hematological origin.
  4. Not having received any treatment that could interfere with the functioning of the bone marrow.
  5. Whose 2 parents or the holder of parental authority have signed a consent enlightened.
  6. Affiliated patient or beneficiary of a social security scheme.

Exclusion Criteria:

* for patients with AL:

  1. Patient under 1 year old and over 15 years old.
  2. Contraindication to myelogram.
  3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
  4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
  5. Having received prior hematological treatments.
  6. Parents with physical or mental condition not allowing to understand the informed consent.
* Control group patients

  1. Patient under 1 year old and over 15 years old.
  2. Having an underlying haematological pathology.
  3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
  4. Having received prior hematological treatments.
  5. Parents with physical or mental condition not allowing to understand informed consent.

Where it's running

• Service d'onco-hématologie pédiatrique -CHRU Tours
  Tours, France Recruiting
• Service de chirurgie orthopédique pédiatrique -CHRU TOURS
  Tours, France Recruiting
• Service d'hématologie biologique-CHRU TOURS
  Tours, France Not yet recruiting

Study contacts

• Principal investigator: Julien LEJEUNE, MD-PhD — University Hospital of TOURS
• Study coordinator: Olivier HERAULT, MD-PhD
• Email: olivier.herault@univ-tours.fr
• Phone: +33(0)234378902

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Biocollection of AML, ALL, or high-risk MDS patients at Nantes

  This project collects extra blood or bone marrow samples from adults with AML, ALL, or high-risk MDS to help INSERM researchers study the disease.

  Recruiting Nantes University Hospital · Nantes · NCT06681363

• Orca-T with myeloablative allogeneic stem cell transplant for advanced leukemias and MDS

  This Phase I study tests whether giving Orca-T alongside standard dual‑agent graft‑versus‑host disease prevention is safe in adults (18–70) receiving a myeloablative allogeneic stem cell transplant for acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06551584

• Brain imaging in young patients with acute leukemia

  This study is testing how chemotherapy affects the brains of children and young adults with acute leukemia to see if it causes any thinking problems and to find ways to help them.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06421155

• Combining Quizartinib with Chemotherapy for Pediatric AML Patients

  This study is testing if adding a new drug called quizartinib to standard chemotherapy can help children with a specific type of leukemia feel better and have better treatment outcomes.

  Recruiting Phase 2 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06262438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.